SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier ...
The recently posted first draft of DSM5 (www.dsm5.org) has suggested a whole new category of mental disorders called the "Behavioral Addictions". The category would begin life in DSM5 nested alongside ...
MIAMI, FL / ACCESS Newswire / July 11, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) today announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback